Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LION: Topical Laquinimod Eye Drops
NCT06161415Phase 1Completed
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of laquinimod in uveitis and inflammation (3 arms). Primary endpoints: Concentration of Laquinimod in aqueous humor and vitreous samples of human participants at 2 weeks and Concentration of Laquinimod in plasma of human participants at 2 weeks. Started May 2024; status: completed.
02
Drugs
laquinimod
03
Conditions
uveitisinflammation
Beyond the preview
Go deeper on NCT06161415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161415.